#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sexually transmitted disease Pemphigoid Li-Fraumeni syndrome Congenital leptin deficiency Friedreich's ataxia Kearns-Sayre syndrome Liposarcoma recurrent Leukaemia Pneumonia Small cell lung cancer Central nervous system neoplasm HER2 gene amplification Fungal infection Neuropathy peripheral Huntington's disease More trials…

    Learn about Rare Diseases

    Shprintzen-Goldberg syndrome – Treatment Angiosarcoma recurrent – Diagnostics Marginal zone lymphoma – Diagnostics Ewing’s sarcoma recurrent – Life with Disease Hereditary hypophosphataemic rickets – Diagnostics Angiosarcoma non-metastatic Hyperoxaluria – Basic Information Breast angiosarcoma – Trials in Disease Acute respiratory distress syndrome – Life with Disease Ornithine transcarbamoylase deficiency – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lenalidomide Varnimcabtagene Autoleucel Resiquimod Sulfate Perindopril Arginine Doxycycline Prasterone Amoxicillin Tasimelteon Rbd4059 Tozinameran Prednisolone Doxylamine Hydrogen Succinate Latozinemab Ck-0045 Acetylcysteine Gsk3965193B Human Immunoglobulin G Arsenic Trioxide Zolbetuximab VAMIFEPORT TRIHYDROCHLORIDE More therapies…

    Learn about Your Condition

    Glomerulonephritis chronic Ureteric cancer Carotid arteriosclerosis Pneumococcal infection Angiosarcoma recurrent Follicular thyroid cancer Brain cancer metastatic HER2 negative breast cancer Oropharyngeal cancer recurrent Shock Generalised anxiety disorder Bronchiectasis Chronic hepatic failure Immunosuppression Demyelination More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University General Hospital Of Thessaloniki Ahepa

University General Hospital Of Thessaloniki Ahepa

1st St Kiriakidis Str, Thessaloniki, 546 36, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

    Recruiting

    3 1
    Investigated Diseases:
    • Glomerulonephritis membranoproliferative
    Investigated Drugs:
    • Iptacopan Hydrochloride
    • Iptacopan
    Czechia Denmark France Germany Greece Italy +4

  • Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial

    Not yet recruiting

    3 1
    Czechia Germany Greece

  • A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Diabetes mellitus
    • Obesity
    • Overweight
    Czechia Germany Greece Poland

  • Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    • Obesity
    • Overweight
    Bulgaria Czechia Denmark France Germany Greece +4

  • A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Czechia Denmark France Germany +8

  • Phase 2 Study of RADAMTS13 in Adults with Acute Ischemic Stroke

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Belgium France Germany Greece

  • Clarithromycin to prevent secondary infections in adult patients with community-acquired pneumonia-related sepsis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Sepsis
    Investigated Drugs:
    • Clarithromycin
    • Water For Injection
    • Glucose Monohydrate
    Greece

  • Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Treprostinil Palmitil
    Austria Belgium Czechia Denmark France Germany +6

  • A study to evaluate the use of meropenem to reduce the risk of sepsis in patients with suspected infection in the emergency department

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Bacterial infection
    • Sepsis
    Investigated Drugs:
    • Meropenem Anhydrous
    • Sodium Chloride
    Greece
Previous Page
1 … 5 6 7 8 9 … 15
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!